Skip to main content
SpringerLink
Log in

Diuretic effect and disposition of furosemide in cystic fibrosis

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacodynamics and kinetics of single oral and intravenous doses of furosemide were studied in 9 patients (mean age 18.5 y) with cystic fibrosis.

The diuretic effect of furosemide lasted for 6 h after oral administration and 2 h following intravenous injection of the drug.

The patients with cystic fibrosis had a more pronounced diuretic response both to the oral and intravenous treatments than that reported in normals. Furosemide caused a marked decrease in urine pH for 5 h following the oral dose and between the 2nd and 3rd h after i.v. injection. The baseline nocturnal urine flow rate in 7 of the 9 patients given furosemide orally was increased by 30.6% compared to that reported in healthy subjects.

The bioavailability of furosemide, its mean absorption rate and the mean plasma and urinary elimination half-lives both of the oral and the intravenous drug were similar to those reported in normal subjects. The patients with cystic fibrosis showed, however, about double normal mean total clearance after both the oral and i.v. treatments, and its renal clearance was almost half the plasma clearance. Nonrenal clearance was markedly increased in the patients, which agreed with a considerable decrease in the renal excretion of the drug. The mean apparent volume of distribution was also markedly increased compared to data in the literature. Oral furosemide resulted in a moderate increase in haematocrit and haemoglobin levels in 7 of 9 patients with cystic fibrosis and marked hypokalemia developed in 6 of the 9 patients 6 h after dosing. Pulmonary function tests performed at that time were changed in an inconsistent manner. The sweat test was significantly perturbed in those subjects, although the concentration of chloride in sweat did not fall below 60 mEq/l in any of the sweat samples tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abramowsky CR, Swinehart GL (1982) The nephropathy of cystic fibrosis. A human model of chronic nephrotoxicity. Hum Pathol 13: 934–939

    Google Scholar 

  2. Ahmad S (1974) Renal insensitivity to frusemide caused by chronic anticonvulsant therapy. Br Med J 3: 657–659

    Google Scholar 

  3. Aladjem M, Lotan D, Boichis H, Orda S, Katznelson D (1983) Renal function in patients with cystic fibrosis. Nephron 34: 84–86

    Google Scholar 

  4. Alván G, Beermann B, Hjelte L, Lind M, Lindholm A, Strandvik B (1988) Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis. Clin Pharmacol Ther 44: 436–441

    Google Scholar 

  5. Andreasen F, Hansen HE, Mikkelsen E (1978) Pharmacokinetics of furosemide in anephric patients and in normal subjects. Eur J Clin Pharmacol 13: 41–48

    Google Scholar 

  6. Andreasen F, Mikkelsen E (1977) Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol 12: 15–22

    Google Scholar 

  7. Batlle DC (1986) Segmental characterization of defects in collecting tubule acidification. Kidney Int 30: 546–554

    Google Scholar 

  8. Bauer WC, Rosenberg BF (1960) A quantitative study of glomerular enlargement in children with tetralogy of Fallot. A condition of glomerular enlargement without an increase in renal mass. Am J Pathol 37: 695–708

    Google Scholar 

  9. Beermann B, Dahlen E, Lindström B, Rosen A (1975) On the fate of furosemide in man. Eur J Clin Pharmacol 9: 57–61

    Google Scholar 

  10. Beermann B, Dahlen E, Lindström B (1977) Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 22: 70–78

    Google Scholar 

  11. Berg U, Kusoffsky E, Strandvik B (1982) Renal function in cystic fibrosis with special reference to the renal sodium handling. Acta Paediat Scand 71: 833–838

    Google Scholar 

  12. Branch RA, Roberts CJC, Homeida M, Levine D (1977) Determinants of response to frusemide in normal subjects. Br J Clin Pharmacol 4: 121–127

    Google Scholar 

  13. Brown RD, Manno JE (1978) ESTRIP and BASIC computer program for obtaining initial polyexponential parametr estimates. J Pharm Sci 67: 1687–1691

    Google Scholar 

  14. Cook AR (1974) Duodenal acidification: role of the first part of the duodenum in gastric emptying and secretion in dogs. Gastroenterology 67: 85–92

    Google Scholar 

  15. Cox KL, Isenberg JN, Asment ME (1982) Gastric acid hypersecretion in cystic fibrosis. J. Pediatr Gastroenterol Nutr 1: 559–565

    Google Scholar 

  16. Cutler RE, Blair AD (1979) Clinical pharmacokinetics of furosemide. Clin Pharmacokinet 4: 279–296

    Google Scholar 

  17. Fine A, Henderson IS, Morgan DR, Tilstone WJ (1977) Malabsorption of frusemide caused by phenytoin. Br Med J 2: 1061–1062

    Google Scholar 

  18. Fondacaro JD, Heubi JE, Kellog FW (1982) Intestinal bile acid malabsorption in cystic fibrosis: a primary mucosal cell defect. Pediatr Res 16: 494–498

    Google Scholar 

  19. Goldfarb J, Worniser GP, Inchiosa MA, Guideri G, Diaz M, Gandhi R, Goltzman C, Mascia AV (1986) Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. J Clin Pharmacol 26: 222–226

    Google Scholar 

  20. de Groot R, Smith AL (1987) Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet 13: 228–253

    Google Scholar 

  21. Guggenbichler JP, Kienel G (1979) Bioavailability of oral antibiotics in cystic fibrosis. Monog Paediat 10: 34–40

    Google Scholar 

  22. Hallynck TH, Soep HH, Thomis JA, Boelaert J, Daneels R, Dettli L (1981) Should clearance be normalized to body surface area or to lean body mass? Br J Clin Pharmacol 11: 523–525

    Google Scholar 

  23. Jasper HH, Ward AA, Pope A (1969) Basic mechanism of epilepsia. Churchill, London, p 647

    Google Scholar 

  24. Jusko WJ, Mosovich LL, Gerbracht LM, Mattar ME, Yaffe SJ (1975) Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics 56: 1038–1044

    Google Scholar 

  25. Kaojarern S, Day B, Brater DC (1982) The time course of delivery of furosemide into urine: An independent determinant of overall response. Kidney Int 22: 69–74

    Google Scholar 

  26. Kelly MR, Cutler RE, Forrey AW, Kimpel BM (1974) Pharmacokinetics of orally administered furosemide. Clin Pharmacol Ther 15: 178–186

    Google Scholar 

  27. Knoppert DC, Spino M, Beck R, Thiessen JJ, MacLeod SM (1988) Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease. Clin Pharmacol Ther 44: 254–264

    Google Scholar 

  28. Lang RE, Thölken H, Ganten D, Luft FC, Ruskoaho H, Unger T (1985) Atrial natriuretic factor — a circulating hormone stimulated by volume loading. Nature 314: 264–266

    Google Scholar 

  29. Lentner C (1981) Geigy scientific tables, vol. 1, Ciba-Geigy Ltd, Basel p 55

    Google Scholar 

  30. MacLusky I, McLaughlin FJ, Levinson H (1985) Cystic fibrosis. Curr Probl Pediat 15: No 6 and 7

    Google Scholar 

  31. McCann EM, Lewis K, Deming DD, Donovan MJ, Brady JP (1985) Controlled trial of furosemide therapy in infants with chronic lung disease. J Pediat 106: 957–962

    Google Scholar 

  32. Michalsen H, Monn E, Bergan T, Churg J, Johannessen JV (1984) Renal biopsy in cystic fibrosis. Pathol Res Pract 178: 261–267

    Google Scholar 

  33. Mogensen CE (1971) Urinary albumin excretion in early and long-term juvenile diabetes. Scand J Clin Lab Invest 28: 183–187

    Google Scholar 

  34. Mogensen CE, Andersen MJF (1973) Increased kidney size and glomerular filtration rate in early juvenile diabetes. Diabetes 22: 706–712

    Google Scholar 

  35. Moore DE (1977) Photosensitization by drugs. J Pharm Sci 66: 1282–1284

    Google Scholar 

  36. Moss AJ (1982) The cardiovascular system in cystic fibrosis. Pediatrics 70: 728–741

    Google Scholar 

  37. Nation RL, Peng GW, Chiou WL (1979) Quantitative analysis of furosemide in micro plasma volumes by high-performance liquid column chromatography. J Chromatogr 162: 88–93

    Google Scholar 

  38. Parsons RL, Paddock M (1975) Absorption of two antibacterial drugs, cephalexin and co-trimoxazole in malabsorption syndromes. J Antimicrob Chemother 1 [Suppl]: 59–67

    Google Scholar 

  39. Prandota J (1980) Studies on furosemide using rats as an experimental model and in children with different diseases. Pediatria Pol 55: 495–501

    Google Scholar 

  40. Prandota J (1983) Pharmacokinetics of furosemide urinary elimination by nephrotic children. Pediat Res 17: 141–147

    Google Scholar 

  41. Prandota J (1986) Pharmacodynamic determinants of furosemide diuretic effect in children. Dev Pharmacol Ther 9: 88–101

    Google Scholar 

  42. Prandota J (1987) Drug disposition in cystic fibrosis. Progress in understanding pathophysiology and pharmacokinetics. Pediat Infect Dis J 6: 1111–1126

    Google Scholar 

  43. Prandota J (1988) Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 35: 542–578

    Google Scholar 

  44. Prandota J, Witkowska M (1976) Pharmacokinetics and metabolism of furosemide in man. Eur J Drug Metabol Pharmacokinet 1: 177–181

    Google Scholar 

  45. Rane A, Villeneuve JP, Stone WJ, Nies AS, Wilkinson GR, Branch RA (1978) Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 24: 199–207

    Google Scholar 

  46. Riva E, Farina P, Tognoni G, Bottino S, Orrico C, Pardi G (1978) Pharmacokinetics of furosemide in gestosis of pregnancy. Eur J Clin Pharmacol 14: 361–366

    Google Scholar 

  47. Rosenthal A, Button LN, Khaw KT (1977) Blood volume changes in patients with cystic fibrosis. Pediatrics 59: 588–594

    Google Scholar 

  48. Rupp W (1974) Pharmacokinetics and pharmacodynamics of Lasix. Scot Med J 19: 5–13

    Google Scholar 

  49. Scott HW, Elliot SR (1950) Renal hemodynamics in congenital cyanotic heart disease. Bull J Hopkins Hosp 86: 58–78

    Google Scholar 

  50. Sirota JH, Baldwin DS, Villareal H (1950) Diurnal variations of renal function in man. J Clin Invest 29: 187–192

    Google Scholar 

  51. Smith DE, Lin ET, Benet LZ (1980) Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. Drug Metab Disposit 8: 337–342

    Google Scholar 

  52. Spino M, Chai RP, Isles AF, Thiessen JJ, Tesoro A, Gold R, MacLeod SM (1984) Cloxacillin absorption and disposition in cystic fibrosis. J Pediatr 105: 829–835

    Google Scholar 

  53. Strober W, Peter G, Schwartz RH (1969) Albumin metabolism in cystic fibrosis. Pediatrics 43: 416–426

    Google Scholar 

  54. Van Caillie-Bertrand M, DeBieville F, Neijens H (1982) Trace metals in cystic fibrosis. Acta Paediat Scand 71: 203–207

    Google Scholar 

  55. Vawter GF, Shwachman H (1979) Cystic fibrosis in adults. An autopsy study. Pathol Annu 14: 357–382

    Google Scholar 

  56. Vert P, Broquaire M, Legagneur M, Morselli PL (1982) Pharmacokinetics of furosemide in neonates. Eur J Clin Pharmacol 22: 39–45

    Google Scholar 

  57. Villeneuve JP, Verbeeck RK, Wilkinson GR, Branch RA (1986) Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol Ther 40: 14–20

    Google Scholar 

  58. Watkins J, Tercyak AM, Szczepanik P, Klein PD (1977) Bile salt kinetics in cystic fibrosis. Influence of pancreatic enzyme replacement. Gastroenterology 73: 1023–1028

    Google Scholar 

  59. Whitman V, Stern RC, Bellet P (1975) Studies on cor pulmonale in cystic fibrosis: I. Effect of diuresis. Pediatrics 55: 83–87

    Google Scholar 

  60. Williamson HE (1986) Interaction of furosemide and phenytoin in the rat. Proc Soc Exp Biol Med 182: 322–324

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. J. Korczak Memorial Children's Hospital, Wrocław, Poland

    J. Prandota

  2. Section on Clinical Pharmacology, Departments of Pharmacology and Therapeutics, and Pediatrics, Louisiana State University Medical Center, USA, Shreveport, LA

    I. J. Smith, B. C. Hilman & J. T. Wilson

Authors
  1. J. Prandota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. J. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. C. Hilman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. T. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prandota, J., Smith, I.J., Hilman, B.C. et al. Diuretic effect and disposition of furosemide in cystic fibrosis. Eur J Clin Pharmacol 40, 333–341 (1991). https://doi.org/10.1007/BF00265840

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00265840

Key words

Search

Navigation